Here, the morphometric study did not reveal any differences in the average cell area, nuclear area, cytoplasm area, or nuclear-cytoplasmic ratio between astrocytes of the control line and the PD mutation line.<h4>Conclusion</h4>Reprogramming and obtaining of astrocytes from iPSCs received from a donor with a PD-associated mutation in the <i>LRRK2</i> gene allow to assess the nature and dynamics of pathological morphochemical and ultrastructural changes caused by the mutation during gliogenesis. This evidence concerns the gene LRRK2 and Parkinson disease.